We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Molecular-Based Techniques Diagnose Leprosy

By LabMedica International staff writers
Posted on 23 Apr 2014
The classic tools to diagnose leprosy are based on bacillary counts and histopathology, but these have been facing hurdles, especially in distinguishing latent infection from active disease and diagnosing paucibacillary clinical forms.

Serological tests and interferon gamma (IFN-γ) releasing assays (IGRA) that employ humoral and cellular immune parameters, respectively, are also being used, but recent results indicate that quantitative polymerase chain reaction (qPCR) is a key technique due to its higher sensitivity and specificity.

Scientists at the Instituto Oswaldo Cruz (Rio de Janeiro, Brazil) have evaluated the various molecular assays now being used to detect Mycobacterium leprae, the causative agent of leprosy. More...
Advances concerning the structure and function of the M. leprae genome led to the development of specific PCR-based gene amplification assays for leprosy diagnosis and monitoring of household contacts.

Some of their findings suggest that commercial kits can be used to extract, purify and amplify M. leprae DNA, ribonucleic acid (RNA), or both. Samples can also be easily stored in 70% ethanol and fast technology for analysis of nucleic acids (FTA) cards (Whatman, Maidstone, UK) for M. leprae DNA detection. Irrespective of whether the detection method used is conventional or real-time PCR, smaller PCR products allow for better amplification efficiency from DNA extracted from either formalin- or ethanol-fixed or fresh tissues. In fact, an important advance has been the real-time PCR technology.

While PCR diagnosis is not needed for lepromatous patients with high bacillary load and high number of lesions, it is extremely helpful for the diagnosis of the situations such as clinical presentations with scarce number of M. leprae bacilli (paucibacillary) and difficult-to-diagnose patients. The detection of M. leprae DNA in different samples of the household contacts of leprosy patients is very promising. Although a positive PCR result is not sufficient to establish a causal relationship with disease outcome, quantitation provided by qPCR is clearly capable of indicating increased risk of developing the disease and could alert clinicians to follow these contacts more closely or even define rules for chemoprophylaxis.

The authors concluded that overall, extensive evaluation of PCR tests in field studies has shown that DNA-based PCR assays can be 100% specific, while the sensitivity ranges from 34% to 80% in patients with paucibacillary forms to greater than 90% in patients with multibacillary forms of the disease. PCR has been ascertained to be especially valuable in diagnosing difficult cases like pure neural leprosy, paucibacillary, and patients with atypical clinical presentation and histopathological features compatible with leprosy. The study was published on April 10, 2014, in the journal Public Library of Science Neglected Tropical Diseases.

Instituto Oswaldo Cruz
Whatman 

Related Links:

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
C-Reactive Protein Rapid Test
Afinion CRP
New
Urine Drug Test
Instant-view® Phencyclidine Urine Drug Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Ear wax could be a possible screening medium for Parkinson’s disease (Photo courtesy of 123RF)

Earwax Test Accurately Detects Parkinson’s by Identifying Odor Molecules

Current tests for Parkinson’s disease (PD) rely heavily on clinical scales and neuroimaging, which are often subjective, expensive, and ill-suited for routine screening. Since most treatments only slow... Read more

Molecular Diagnostics

view channel
Image: Capsule sponge opened to reveal the sponge (Photo courtesy of StillVision)

Capsule Sponge Test Could Replace Endoscopies for Monitoring Esophageal Cancer Risk

Esophageal cancer remains a challenging disease to treat, with fewer than 20% of patients surviving beyond five years of diagnosis—a statistic that has remained largely unchanged for decades.... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The new tool shines a light on elusive genomic patterns (Photo courtesy of Adobe Stock)

Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance

Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.